LEGN Legend Biotech Corp IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1801198 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY64.0%
TTM net income YoY-67.7%
TTM EPS YoY-68.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin61.4%
Operating margin—
Net margin-28.8%
FCF margin-12.5%
EBITDA margin—
Returns
ROE-29.1%
ROA-17.4%
ROIC (approx.)—
Asset turnover0.60x
Leverage & solvency
Liabilities / assets42.2%
Debt / equity0.32x
Current ratio1.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.34x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.03B | $627.30M | $285.10M | $117.00M | $68.83M |
| Cost of revenue | $397.10M | $216.40M | $144.20M | $65.36M | $0 |
| Gross profit | $631.80M | $410.90M | $140.90M | $51.64M | $68.83M |
| R&D expense | $414.70M | $413.50M | $382.20M | $335.65M | $313.35M |
| Operating income | -$136.50M | -$309.50M | -$528.10M | — | — |
| Interest expense | $21.40M | $21.60M | $21.80M | $10.80M | $900,000 |
| Pretax income | -$282.60M | -$158.10M | -$520.20M | -$445.72M | -$407.20M |
| Income tax | $14.20M | $18.90M | -$1.90M | $625,000 | -$3.61M |
| Net income | -$296.80M | -$177.03M | -$518.25M | -$446.35M | -$403.58M |
| EPS (basic) | -0.81 | -0.48 | -1.47 | -1.40 | -1.43 |
| EPS (diluted) | -0.81 | -0.48 | -1.47 | -1.40 | -1.43 |
| Weighted avg. shares (diluted) | 368.64M | 365.70M | 352.17M | 318.08M | — |
| Balance sheet | |||||
| Cash & equivalents | $901.90M | $286.70M | $1.28B | $786.00M | $688.94M |
| Receivables | $13.10M | $6.40M | $100.04M | $90,000 | $50.41M |
| Inventory | $32.00M | $23.90M | $19.43M | $10.35M | $1.75M |
| Current assets | $1.25B | $1.28B | $1.50B | $1.10B | $949.85M |
| PP&E, netmay include right-of-use assets (IFRS) | $116.30M | $99.30M | $108.80M | $105.17M | $102.51M |
| Intangibles | $1.90M | $2.20M | $4.06M | $3.41M | $4.68M |
| Total assets | $1.73B | $1.67B | $1.85B | $1.33B | $1.12B |
| Current liabilities | $636.40M | $277.70M | $216.42M | $297.79M | $229.20M |
| Short-term debt | $319.10M | $0 | — | — | — |
| Long-term debt | $0 | $301.20M | $281.33M | $260.93M | $120.46M |
| Total debt | $319.10M | $301.20M | $281.33M | $260.93M | $120.46M |
| Total liabilities | $731.60M | $629.60M | $597.24M | $586.65M | $353.52M |
| Shareholders' equity | $1.00B | $1.04B | $1.25B | $744.31M | $765.94M |
| Net debt | -$582.80M | $14.50M | -$996.37M | -$525.07M | -$568.48M |
| Cash flow statement | |||||
| Operating cash flow | -$100.20M | -$144.00M | -$393.30M | -$201.28M | -$198.47M |
| Capital expenditure | $28.60M | $14.10M | $20.10M | $20.93M | $42.20M |
| Free cash flow | -$128.80M | -$158.10M | -$413.40M | -$222.21M | -$240.66M |
| Investing cash flow | $709.60M | -$850.60M | $92.90M | -$77.09M | -$194.98M |
| Financing cash flow | -$300,000 | $5.70M | $791.40M | $377.98M | $626.66M |
| Stock-based compensation | $64.60M | $68.90M | $47.70M | $34.34M | $20.16M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.